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Abstract Many effect measures used in clinical trials are
problematic because they are differentially understood by
patients and physicians. The emergence of novel methods such
as accelerated failure-time models and quantile regression has
shifted the focus of effect measurement from probability
measures to time-to-event measures. Such modeling tech-
niques are rapidly evolving, but matching non-parametric
descriptive measures are lacking. We propose such a measure,
the delay of events, demonstrating treatment effect as a gain in
event-free time. We believe this measure to be of value for
shared clinical decision-making. The rationale behind the
measure is given, and it is conceptually explained using the
Kaplan–Meier estimate and the quantile regression frame-
work. A formula for calculation of the delay of events is given.
Hypothetical and empirical examples are used to demonstrate
the measure. The measure is discussed in relation to other
measures highlighting the time effects of preventive treat-
ments. There is a need to further investigate the properties of
the measure as well as its role in clinical decision-making.
Keywords Clinical trials  Randomized 
Kaplan–Meier survival curves  Preventive measures 
Treatment Outcome
Many chronic diseases develop over long time periods,
where the risks of serious adverse symptomatic events
increase with time. Prevention aims at reducing such risks,
either by reducing the event rate or by delaying the timing
of the events. The effect of a preventive intervention is
preferably evaluated in a controlled trial where one or more
binary outcomes are monitored continuously during the
study period. Given such data, there are several ways of
examining the effect of the treatment. At any given point in
time, the proportions of events in the trial arms may be
compared in relative or absolute terms. Other statistical
options include the use of time-to-event data to compare
the rates, risks or hazards of events during specified time
periods. While all these measures are methodologically
justified and well used, there is an ongoing debate about
which one to prefer, as the choice of effect measure has
been shown to affect clinical decision-making [1–7]. The
difficulty for physicians and patients to grasp and agree on
the chance and magnitude of a preventive treatment evi-
dence based effect is a challenge to informed decision-
making, and more generally to the idea of evidence based
clinical practice.
This may, however, change with the development of
new methods for assessing and illustrating treatment
effects, such as accelerated failure-time models (AFT) and
quantile regression. AFT models are similar to Cox mod-
els, but include a parameterization of the baseline hazard,
and give results on the time scale instead of the hazard
scale. Quantile regression goes beyond regression models
for the conditional mean, and extends the regression model
to conditional quantiles of the outcome variable, which
offers a more comprehensive analytical approach.[8, 9]
Such modeling techniques are rapidly evolving in many
scientific fields, including biomedical sciences.[10–12]. In
terms of assessing treatment effect, these techniques have
shifted the focus from investigating probability measures at
specific time points, beyond summary time-to-event
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measures, to assessment of how the effect develops over
time. There has, however, been a lack of a non-parametric
descriptive measure that matches these approaches.
In this article we propose an alternative way to illustrate
treatment effects from randomized controlled trials,
matching the AFT and quantile regression modeling
frameworks. By using time-to-event data, it is possible to
calculate treatment effect as the delay of events, (DoE) i.e.
the time a disease event is delayed due to treatment. We
believe that expressing treatment effect as a potential gain
in disease-free time is easy to understand for patients, and
that the measure, therefore, may be of value in clinical
practice.
Measuring treatment effect as delay of events
Assessment of the delay of events may be explained using
a Kaplan–Meier graph. The Kaplan–Meier estimator is a
non-parametric estimator from incomplete observations,
which means that the estimator can account for censored
data [13]. This is commonly the case in clinical trials
investigating a treatment’s ability to prevent clinically
significant adverse events of chronic diseases. Figure 1
presents the Kaplan–Meier curves (survival curves) for the
endpoint all-cause mortality in the Scandinavian Simva-
statin Survival Study (4S), a randomized controlled trial
presenting the first evidence that statin treatment improves
survival in patients with coronary heart disease [14]. While
the vertical difference between the two trial arms repre-
sents the difference in proportions of patients still alive at a
given point in time, the horizontal difference represents a
time discrepancy when the study arms have obtained equal
proportions or quantiles of survivors. That time difference
equals the time delay of the incidence between the groups,
in other words the delay of events in patients suffering such
events during the study. The delay of events is possible to
calculate and plot as a function of follow-up time itself,
assuming that the Kaplan–Meier curves are nearly unbi-
ased estimators of the true survival curves [15]. The
mathematical expression of the delay of events is explained
in appendix.
Empirical and hypothetical examples
Figure 2 presents the delay of events curve (with a shad-
owed 95 % confidence interval) based on the survival data
presented in Fig. 1. The delay of events curve demonstrates
no beneficial effect during the first year of treatment. After
3 years of treatment, the delay of events is approximately
half a year, and at the end of the study it has reached about
1 year, indicating that persons in the treatment arm who
developed an event by the end of the 4S study period had
delayed that event for 1 year compared to patients in the
control arm.
The corresponding Kaplan–Meier and delay of events
curves for the endpoint major coronary events in the 4S
study are demonstrated in Fig. 3a, b. A statistically
Fig. 1 Kaplan–Meier curves for all-cause mortality from the 4S
study. The vertical difference between the curves represents a
difference in proportions, at different time points. The horizontal
difference between the curves represents a time difference when the
cumulative incidence is equal, which corresponds to the time an event
is delayed
Fig. 2 The delay of event curve (with shadowed 95 % confidence
intervals) for the endpoint total mortality in the 4S study
904 P. Lytsy et al.
123
significant (at the P \ 0.05 level) delay of events for
endpoint major coronary events is obtained after 1.5 years,
and the maximum delay reaches about 1.75 years at the
end of the study period.
Generally, the delay of events curve cannot always be
expected to increase, not even within a study period. At
some point, if the follow-up is long enough, it will decrease
until it no longer demonstrates a superior effect, for
example due to an aging study sample, competing events,
or a time-limited treatment effect. Determining when a
delay of events curve falls below a level of effect regarded
not to be clinically significant may be of value in order to
agree on recommendations for treatment discontinuation.
Figure 4 presents four hypothetical intervention studies
illustrating the delay of events when the survival curves
(a) diverge, (b) diverge after an initial latency period,
(c) diverge initially followed by parallel survival curves
and (d) cross over during the study period.
Why another effect measure?
It is well known that the established effect measures are
associated with some difficulties when used in clinical care
for individual decision-making. One problem involves the
fact that they are probability measures. Probabilistic
thinking is difficult. Laymen, patients, and even skilled
professionals all suffer from various degrees of statistical
illiteracy, making it difficult for many to perform simple
arithmetic calculations and to comprehend risk estimates
[16–18]. This predicament is further supported by research
showing that the format of the effect measure may influ-
ence patients’ acceptance of taking a medication [1, 2, 7] as
well as doctors’ and health authorities’ willingness to
recommend or prescribe it [3, 19]. This signifies the chal-
lenge clinicians face when deciding how to describe
treatment outcomes to their patients for the purpose of
shared decision-making.
The time-limited follow up in randomized controlled
trials might also flaw the understanding of a treatment’s
effect, since it does not apply to a patient’s lifetime per-
spective. The fact that a treatment, relative to a control
group, e.g. decreases the risk of death by 30 % may be
accurate during the study period, but become less true the
longer the results are extrapolated, and is bizarre if
extrapolated to a lifetime perspective. For this reason,
many health professionals advocate using absolute mea-
sures of effect (or its reciprocal: the numbers needed to
treat) when presenting treatment effect to patients. How-
ever, absolute measures may portray the view that avoid-
ance of events within the study period is the only benefit of
a treatment, suggesting that the effect is obtained in a
limited number of individuals. There is little support that
such an interpretation of beneficial effects from preventive
treatment is reasonable, given that no probability measure
has the ability to tell if a treatment effect is obtained in a
large or a small number of the treated population [20]. It is
even possible that every treated patient benefits to a small
degree, but that in many patients such advantage will occur
beyond the study time frame. Notably, these time con-
straints also apply to the delay of events, but are more
easily spotted here than in probability measures because
the delay of events curve (and indeed the Kaplan–Meier
Fig. 3 Kaplan-Meier curves for major coronary events* in the 4S
study (a) and the consecutive delay of event curve with shadowed
95 % confidence interval (b). *Major coronary events comprised
coronary deaths, definite or probable hospital-verified non-fatal acute
MI, resuscitated cardiac arrest, and definite silent MI verified by
electrocardiogram
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curve) highlights variation in treatment effect as a function
of time itself.
Based on the understanding of how common diseases,
such as cardiovascular disease, develop over a life span, it is
likely more correct to assume that prevention postpones
disease events rather than entirely avoids them. From the
perspective of individuals, it would therefore be of value to
report the time an event may be delayed, rather than a
probability measurement of the likelihood of being event-
free at a given time point. That kind of reasoning is well
adopted in other medical fields, such as oncology, in which
randomized controlled trials often continue until a defined
proportion of patients in the study groups have developed a
certain endpoint. The effect of treatment in such studies is
thus reported as a gain in disease-free time. Another medical
field emphasizing time as a major dimension of interest is
global health, in which life expectancy and quality-adjusted
life years frequently are used as measures of health and
disease burden. Further, the delay of events is a descriptive
measure that conceptually matches the increasingly recog-
nized AFT and quantile regression modeling techniques.
Clinical use of the delay of events
It has been shown that presenting effect as gain in event-
free time, rather than cumulative probability, seems to
increase a treatment’s attractiveness [21]. Furthermore, the
size of the time delay seems to be related to peoples’
motivation to take a medication [22].
If a patient is asked to presume that he or she will
develop the event within the length of the study period, the
delay of events will serve as an estimation of the magnitude
of the treatment effect developing over time. Based on the
delay of events curve from the 4S study, patients eligible




Fig. 4 a Kaplan Meier curves of four hypothetical intervention
studies and their subsequent delay of event curves. Y-axes on the left
correspond to the proportion of event free subjects in the compared
groups; Y-axes on the right represent the time units used in each
study. Diverging survival curves will present an increasing delay of
events curve within the study time period. b Survival curves that are
diverging after an initial latency period will present a delay of events
curve where the effect is delayed; in this case the effect becomes
apparent after about 2 years. c Survival curves diverging initially
followed by parallel development over time will present a delay of
event curve demonstrating a sustained effect, which in this case after
2 years of treatment approximates from between 1 and 2 years until
the end of follow-up. d Survival curves diverging and crossing over
during the study period will demonstrate a delay of events curve
where the positive effect seen first diminishes and then provides a
negative effect. A negative delay of events curve should be
interpreted as if the active treatment causes harm, as demonstrated
by a higher event rate in the treated group
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following: ‘‘You have an unnecessarily high risk of
developing a major coronary event. No one can tell for sure
if or when this will occur in your case. Presuppose that you
actually would develop this event within the next 5 years;
then taking this treatment during that time will postpone
the event by up to approximately 1.75 years.’’ Hence, the
delay of events curve from a trial will serve as an estimate
of relevance for most individuals eligible for treatment.
Critical appraisal of the delay of events
The delay of events curve is an alternative way to sum-
marize and describe time-to-event data, and as such the
curve will exhibit the same properties and restraints as
Kaplan–Meier curves. Calculating the delay of events
curve does not require any assumptions to be made about
the distribution of the data.
There are several other measures of effect highlighting
the time perspective. There are models that estimate the
mean residual life and cumulative treatment effects [23,
24] as well as direct assessments of the gain in life
expectancy [25, 26]. The gain in life expectancy compares
mean (event-free) survival times in two study groups, and
hence demands a follow-up until every patient and control
has died (or developed the event). Another way to assess a
treatment’s effect as a time variable is the gain in median
survival time. The median survival time measure demands
a follow-up until at least half of the study groups have died
or developed the event, and is thus rarely convenient as an
outcome measure in studies assessing rare events, which is
commonly the case in preventive medicine. The delay of
events curve has an advantage in that sense, since it is also
possible to calculate in studies with low event rates and
high numbers of right-censored patients.
Most measures utilizing survival time in clinical trials
are variants of the relation between the areas under event-
free curves at a given time point, which are two-dimen-
sional measures of person-years. These areas reflect the
entire event occurrences in the study arms during follow-up
until that time point, and are hence summary measures.
Their relation cannot be used to calculate a difference in
time to attain a certain cumulative incidence, as it includes
events when the worse-off group has reached a cumulative
incidence that is not reached by the better-off group.
Conceptually, the delay of events applies best to out-
comes that are inevitable, such as mortality. If the delay of
events is assessed for other outcomes, it is important to
regard and manage the possibility of competing risks,
where one option might be using composite endpoints of
the event of interest and death from other cause. It is
suggested that the problem with competing risks is an area
for future research for the measure.
In theory, presenting an effect as delay of events is most
appropriate when assessing the effect of prevention of
chronic disease events. The method may, however, be used
for any intervention influencing the timing of adverse
clinical events.
As this is a new effect measure, several questions
remain to be answered. These include determination of the
influence of potential confounders on the outcome; how the
accuracy of the results is affected by the sample size, and
how the measure relates to subgroups of patients with
different baseline risks. There is also a need to discuss and
establish guidelines about how the measure should be used,
presented and interpreted within specific research areas.
Such guidelines might include directives of a priori defined
time points, or quantiles of survival-time of interest, as well
as determining what effect should be regarded as clinically
significant at these time points or quantiles. It is also
suggested that future research investigate the measure’s
potential value and limitations when using observational
data, such as cohort studies.
When Wright and Weinstein standardized gains in life
expectancy from a variety of medical interventions, they
concluded that a life gain of 1 month or more following a
preventive intervention was to be considered large in
populations with average risk [26]. What patients regard as
significant in terms of delay of disease probably depends
on several factors, including their individual situations,
knowledge of the disease and the therapy (including
awareness of side-effects) as well as their attitudes and
intrinsic values. Thus, there is a need to investigate how
treatment effect expressed as delay of events is valued in
different populations, and how it affects decision-making.
Conclusion
The delay of events is an effect measure that may be
calculated using time-to-event data. The measure describes
preventive treatment effect as the time an event may be
delayed due to treatment. We believe this way of pre-
senting treatment effect is easy to understand for individ-
uals, making it suitable for use in the clinical situation
when physicians explain outcomes to patients. The delay
of events measure should not replace the established effi-
cacy measurements. Rather, it is suggested that it be
considered a complementary way to present treatment
effect from clinical trials. Since this is a new effect mea-
sure, there is a need to further understand its strengths and
limitations, as well as investigate how it affects clinical
decision-making.
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Appendix
Consider right-censored data with niði ¼ 1; 2Þ observations
from two independent groups of individuals, where Group
1 is the better-off group and Group 2 is the worse-off
group:
ðt11; d11Þ; ðt12; d12Þ; . . .; ðt1n1 ; d1n1Þ and
ðt21; d21Þ; ðt22; d22Þ; . . .; ðt2n2 ; d2n2Þ
where tij is the survival or censoring time for the jth
observation from group i,
dij ¼ 1 if tij is uncensored and dij ¼ 0
if tij is censored:
For convenience we assume that ti1\ti2\ti3\   \tini :






ni  j þ 1
 dij
:
Here kit is the value of ki such that ti 2 ½tki ; tkiþ1:
The aim is to estimate the difference D(t) (delay of
event) in time when the groups show
equal survival incidence, expressed as a function of
time. The estimator of D(t) is d(t) which is given by 7
dðtÞ ¼ s11 ðs2ðtÞÞ  t:
A confidence interval for D(t) may be obtained with the
bootstrap percentile method: 10,000 bootstrap samples of
(tij; dij) are drawn and from each sample and d(t) is
calculated in each bootstrap sample. The 2.5 and 97.5
percentiles in the distribution of the 10,000 estimates are
the limits of a 95 % confidence interval for D(t).
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